NASDAQ: VSTM
Verastem Inc Stock

$6.40-0.17 (-2.59%)
Updated Mar 26, 2025
VSTM Price
$6.40
Fair Value Price
$1.04
Market Cap
$329.51M
52 Week Low
$2.10
52 Week High
$13.52
P/E
-1.75x
P/B
-11.4x
P/S
18.46x
PEG
N/A
Dividend Yield
N/A
Revenue
$10.00M
Earnings
-$130.64M
Gross Margin
100%
Operating Margin
-1,258.9%
Profit Margin
-1,306.4%
Debt to Equity
-4.51
Operating Cash Flow
-$105M
Beta
1.44
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A

VSTM Overview

Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine VSTM's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
VSTM
Ranked
#184 of 479

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important VSTM news, forecast changes, insider trades & much more!

VSTM News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how VSTM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

VSTM ($6.40) is overvalued by 512.83% relative to our estimate of its Fair Value price of $1.04 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
VSTM ($6.40) is not significantly undervalued (512.83%) relative to our estimate of its Fair Value price of $1.04 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
VSTM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VSTM due diligence checks available for Premium users.

Valuation

VSTM fair value

Fair Value of VSTM stock based on Discounted Cash Flow (DCF)

Price
$6.40
Fair Value
$1.04
Overvalued by
512.83%
VSTM ($6.40) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VSTM ($6.40) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VSTM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

VSTM price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-1.75x
Industry
-115.59x
Market
31.65x

VSTM price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
-11.4x
Industry
4.53x

VSTM's financial health

Profit margin

Revenue
$0.0
Net Income
-$64.6M
Profit Margin
0%
VSTM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
VSTM's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$101.5M
Liabilities
$130.4M
Debt to equity
-4.51
VSTM's short-term assets ($94.96M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VSTM's long-term liabilities ($99.46M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VSTM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
VSTM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$25.1M
Investing
$0.0
Financing
$742.0k
VSTM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

VSTM vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
VSTMC$329.51M-2.59%-1.75x-11.40x
SLDBF$330.12M-5.12%-1.39x2.41x
BNTCC$328.56M-4.50%-1,401.00x4.33x
ARCTD$324.08M-6.42%-3.98x1.34x
ZBIOC$336.90M-11.53%-0.68x1.08x

Verastem Stock FAQ

What is Verastem's quote symbol?

(NASDAQ: VSTM) Verastem trades on the NASDAQ under the ticker symbol VSTM. Verastem stock quotes can also be displayed as NASDAQ: VSTM.

If you're new to stock investing, here's how to buy Verastem stock.

What is the 52 week high and low for Verastem (NASDAQ: VSTM)?

(NASDAQ: VSTM) Verastem's 52-week high was $13.52, and its 52-week low was $2.10. It is currently -52.66% from its 52-week high and 204.76% from its 52-week low.

How much is Verastem stock worth today?

(NASDAQ: VSTM) Verastem currently has 51,486,705 outstanding shares. With Verastem stock trading at $6.40 per share, the total value of Verastem stock (market capitalization) is $329.51M.

Verastem stock was originally listed at a price of $133.08 in Jan 27, 2012. If you had invested in Verastem stock at $133.08, your return over the last 13 years would have been -95.19%, for an annualized return of -20.82% (not including any dividends or dividend reinvestments).

How much is Verastem's stock price per share?

(NASDAQ: VSTM) Verastem stock price per share is $6.40 today (as of Mar 26, 2025).

What is Verastem's Market Cap?

(NASDAQ: VSTM) Verastem's market cap is $329.51M, as of Mar 27, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Verastem's market cap is calculated by multiplying VSTM's current stock price of $6.40 by VSTM's total outstanding shares of 51,486,705.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.